3035results about "Bacterial antigen ingredients" patented technology

The present invention relates to the field of bioengineering, and in particular to a modified Bordetella pertussis strain, wherein the mltA gene and the pldA gene are mutated, thereby having an increased bacterial outer membrane vesicle (OMV) yield. The present invention also relates to a method for producing the modified Bordetella pertussis strain and a method for producing OMVs by the modified Bordetella pertussis strain.

The invention discloses a modified bordetella pertussis strain and an application thereof. The modified Bordetella pertussis strain is characterized in that in the Bordetella pertussis strain BAA-589, the BP2992 protein is not expressed, or the inactive BP2992 protein is expressed, the pldA protein is not expressed, or the inactive pldA protein is expressed, and the mla F protein is not expressed, or the inactive mla F protein is expressed. When the Bordetella pertussis strain is treated by combining an ultrasonic method, compared with wild Bordetella pertussis BAA-589, the Bordetella pertussis strain has a remarkable high-foaming phenotype, the OMV secretion amount is remarkably increased, and a good technical foundation is laid for developing a Bordetella pertussis OMV vaccine.

The invention discloses an immune composition containing a fatty acid modified SpyCatcher protein and a preparation method of the immune composition, and belongs to the field of biological medicines. Wherein the SpyCatcher protein (LipoSC) can be self-polymerized into nanoparticles, the SpyCatcher protein (LipoSC) is covalently linked with an antigen containing SpyTag polypeptide through an isopeptide bond, so that the immunogenicity of the loaded antigen can be improved, and a coronavirus spike protein (S protein) receptor binding domain (RBD) is taken as an example. The immune composition containing the fatty acid modified SpyCatcher protein and the coronavirus RBD antigen disclosed by the invention can induce strong RBD specific immune response, and particularly can induce mucosal immunity and humoral immunity of antigen specificity as a mucosal subunit vaccine. The invention further provides a method for finishing fatty acid modification of the SpyCatcher protein in escherichia coli and a method for preparing various immune compositions by using the fatty acid modified protein.

The invention belongs to the field of animal vaccines, and particularly relates to a multi-epitope fusion protein aiming at multi-serotype laisseria parasuis antigen and application. The applicant carries out proteomics analysis on four clinical isolated strains of serotypes 4, 5 and 13 of the parasuis leather serotype 4, 5 and 13 with high toxicity and good immunogenicity, and eight antigen proteins are screened out of the four clinical isolated strains of the serotypes 4, 5 and 13 of the parasuis leather serotype 4, 5 and 13. And further analyzing the screened eight antigen proteins to finally obtain the antigen multi-epitope fusion protein with immunogenicity capable of recognizing three serotypes. When the fusion protein is used as a vaccine, the protection rate of clinically separated piglets infected with a serum type 4 strain HB04, a serum type 5 strain SJZ05 and a serum type 13 strain GD20 reaches 100%.

The invention discloses a Graisseria parasuis three-component subunit vaccine and a preparation method thereof, and belongs to the technical field of biology. The vaccine comprises three kinds of antigen proteins of the Gleisseria parasuis in an immunizing dose and a pharmaceutically acceptable adjuvant, and the amino acid sequences of the three kinds of antigen proteins are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3. The invention further discloses a preparation method of the vaccine. The three-component subunit vaccine provided by the invention has cross protection force on infection of type-4 and type-5 Graisseria parasuis, has an excellent immune protection effect, and is expected to play a better role in prevention and control of infectious diseases caused by the Graisseria parasuis.

The invention provides a method for genetically modifying bordetella pertussis and application of the method. The method comprises the following steps: knocking down or knocking out a first nutrition screening gene of bordetella pertussis to generate a first auxotrophic cell; replacing the first genetic element with a second nutrition screening gene through recombination treatment to obtain a second auxotroph cell; replacing the second nutritional screening gene with the genetically modified second genetic element through recombination treatment to obtain a third nutritional deficient cell; and restoring the first nutritional screening gene to the genome of the third nutritional deficient cell through recombination treatment. In the modification process, use of antibiotics is not involved, no redundant fragments are introduced except for target modification sites, and the method has the advantages that the genetic background purity is high, and no biological safety risk exists in the modification process.

The invention relates to the technical field of biology, in particular to a multivalent pneumococcal polysaccharide-protein conjugate vaccine for preventing pneumococcal infection and respiratory syncytial virus infection as well as a preparation method and application of the multivalent pneumococcal polysaccharide-protein conjugate vaccine. According to the multivalent pneumococcal polysaccharide-protein conjugate vaccine disclosed by the invention, carrier protein is RSV recombinant protein with immunogenicity; the pneumococcal polysaccharide is connected with the RSV recombinant protein through a covalent bond; the RSV recombinant protein is selected from Pre-F protein, and the amino acid sequence of the RSV recombinant protein is shown as SEQ ID NO: 2 or SEQ ID NO: 3. The conjugate vaccine provided by the invention is an innovative vaccine, two common diseases, namely pneumonia and respiratory syncytial virus infection, can be simultaneously prevented by using one vaccine product, and the number of vaccination times of the vaccine is greatly reduced. According to the invention, the carrier protein in the conjugate vaccine is subjected to mutation modification, so that the carrier protein can maintain structural stability and antigen cluster function in different environments.

The discovery and application of immune checkpoint inhibitors (ICI) have significantly promoted cancer treatment. However, the response rate is still low in gastrointestinal (GI) cancers. To explore novel adjuvant treatment options, we performed fecal microbiota transplantation (FMT) of healthy donors on 10 GI cancer patients with resistance to anti-PD-(L) 1 treatment. The combination of FMT and anti-PD1 treatment was well tolerated and no serious adverse reaction was observed. Two out of 10 patients restored clinical responsiveness to anti-PD1 after FMT. Clinical benefits were shown to be associated with better colonization of co-occurred immunogenic microbes from donors, alongside activated immune status reflected by the peripheral immune cell population. Moreover, we identified microbial signatures of ICI responsiveness and validated in an independent cohort. Our study demonstrates the feasibility of FMT as a potential adjuvant therapy for ICI irresponsive GI cancer patients and laid a foundation for LBP / consortia development to enhance ICI efficacy.

The invention belongs to the technical field of biology, and discloses application of a mycoplasma hyopneumoniae Ebh GA protein in preparation of mycoplasma hyopneumoniae or a multi-combined vaccine containing the mycoplasma hyopneumoniae. The applicant screens out the Ebh GA protein with immunogenicity from the mycoplasma hyopneumoniae for the first time, the Ebh GA protein is shown in SEQ ID NO.7 and can be used as a mycoplasma hyopneumoniae subunit vaccine, and therefore the applicant screens out the protein with immunogenicity of other pathogenic bacteria at the same time and combines the protein with the protein into a quadruple subunit vaccine. The antigens of the obtained quadruple vaccine have a synergistic effect, and compared with a single dose, the quadruple vaccine can enhance the immune effect of the quadruple vaccine.

The invention belongs to the technical field of medical biology, and particularly discloses a mycoplasma hyopneumoniae recombinant antigen, an expression vector, a recombinant bacterium and application. The invention provides a construction method of a mycoplasma hyopneumoniae recombinant antigen, which is characterized in that a mycoplasma hyopneumoniae P97 protein R1 region is modified to construct the mycoplasma hyopneumoniae recombinant antigen as shown in SEQ ID No.1. The mycoplasma hyopneumoniae recombinant antigen is cloned into an expression vector, and a recombinant engineering bacterium is obtained by using a genetic transformation means. The recombinant engineering bacterium can stably express the recombinant antigen of the mycoplasma hyopneumoniae, can be prepared into an oral living bacterium preparation, has the characteristics of safety, effectiveness, rapidness and the like, and particularly can prevent infection of the mycoplasma hyopneumoniae to pigs without an immune response process.

Disclosed are immunologically active saponin fraction composition, its method of manufacture and use in vaccine adjuvants, and in adjuvanted vaccines. Methods of preparation, vaccine and treatment kits comprising the adjuvants, and uses of vaccines and vaccine kits comprising the adjuvants are also disclosed.

The invention relates to a fusion protein, an immunogenic composition and a recombinant degenerate vaccine for preventing and treating infection of various pathogenic streptococci, as well as a molecular architecture design, application and the like. According to the invention, three immune antigens, namely an elongation factor Tu (Tuf), a molecular chaperone DnaK and an elongation factor G (fusA), are screened, and it is proved that fusion protein molecules of the three antigens can significantly inhibit tissue lesions caused by infection of different serotypes and different types of streptococci, have good immunogenicity, play roles in immune protection and effective prevention and treatment, and have good application prospects. The bacillus subtilis has the characteristics of broad-spectrum and high-efficiency prevention of streptococcus bacterial infection, and has a wide application prospect.

The invention relates to the technical field of biology, in particular to a polyvalent pneumococcal polysaccharide-protein conjugate composition for preventing pneumococcal infection and VZV infection as well as a preparation method and application of the polyvalent pneumococcal polysaccharide-protein conjugate composition. According to the composition containing the multivalent pneumococcal polysaccharide-protein conjugate, an adopted carrier protein is a VZV recombinant protein with immunogenicity; the pneumococcal polysaccharide is connected with the VZV recombinant protein through a covalent bond; the VZV recombinant protein is selected from gE protein, and the amino acid sequence of the VZV recombinant protein is shown as SEQ ID NO: 3 or SEQ ID NO: 4. Aiming at the main epidemic condition of specific serotype pneumococcus in China, serotype combinations of 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F are creatively selected, so that the composition containing the multivalent pneumococcus polysaccharide-protein conjugate, which is designed aiming at the epidemic condition of the specific serotype pneumococcus in China, is developed.

The invention provides a chemically modified tetanus toxin C fragment as well as preparation and application thereof. The method for chemically modifying the tetanus toxin C fragment comprises the following steps: 1) reacting the tetanus toxin C fragment with a reducing agent to reduce a disulfide bond in the tetanus toxin C fragment; and 2) carrying out a reaction on the reduced tetanus toxin C fragment and an alkylation reagent, and carrying out modification. The recombinant tetanus toxin C fragment prepared by the method disclosed by the invention not only meets the quality standard required by pharmacopeia, but also has the advantages of stable conformation, high yield, easiness in amplification and low cost, and has a wide application prospect in the preparation of human vaccines, veterinary vaccines and antibody drugs and the development process of in-vitro diagnostic reagents.

The invention provides a subunit vaccine for resisting poultry clostridium perfringens, which is characterized in that CPA and NetB proteins are truncated, and three gene sequences of auxiliary protease Fba are connected in series and fused through Linker to obtain recombinant protein. Immunogenicity detection on the N-C-F recombinant protein finds that the N-C-F recombinant protein can induce SPF chicken to generate antibodies. Immune protection test results show that the subunit vaccine prepared from the N-C-F protein and the adjuvant can achieve 100% immune protection effect when being used for immunizing 100 [mu] g / chicken and 200 [mu] g / chicken, and the subunit vaccine can be used as a subunit vaccine for resisting various toxin types.

The invention discloses an mRNA-LNPs Brucella vaccine, an expression vector and a preparation method thereof. The mRNA-LNPs Brucella vaccine comprises at least one of mRNA of an outer membrane protein BP26 and mRNA of an outer membrane protein Omp 25. According to the present invention, the antigen sequence is optimized, the prepared mRNA Brucella vaccine can stimulate the body to produce strong immunogenicity, and compared with the Brucella vaccine prepared before the sequence optimization, the antibody titer is significantly improved. A mouse immune experiment research result shows that high-titer IgG, IgG1 and IgG2a can be generated. Th1 type reaction, Th2 type reaction or mixed Th type reaction is successfully induced.

The invention discloses a mycoplasma hyopneumoniae multi-antigen fusion protein and a vaccine composition and application thereof, and belongs to the technical field of genetic engineering and vaccines. The fusion protein comprises an escherichia coli heat-labile enterotoxin LTB, a mycoplasma hyopneumoniae antigen protein P97R1, a mycoplasma hyopneumoniae lipoprotein 418 and a mycoplasma hyopneumoniae surface antigen protein P46 from the N terminal to the C terminal in the sequence. The vaccine composition comprises the fusion protein and an adjuvant acceptable in veterinary medicine. A vaccine prepared from the fusion protein has the advantages of higher pertinence and immunogenicity, the cell and humoral immune response level is remarkably improved, and meanwhile, the fusion protein is easy to purify and prepare and suitable for large-scale industrial production.

The present invention relates to the field of veterinary vaccines, and discloses the development and application of a subunit vaccine for porcine contagious pleuropneumonia. The TbpB-C truncated protein and the AdhE whole protein selected in the antigen protein combination of the vaccine of the present invention are highly homologous in all APP serotypes, and are prepared into subunit vaccines that can provide cross protection to porcine actinobacillus pleuropneumoniae of different serotypes, and the protection rates against APP1 type and APP3 type strains are both 100%. The truncated proteins selected in the antigen protein combination of the present invention are successfully expressed in a soluble form after optimization, and are easy to express and purify in large quantities, thereby reducing production costs. The present invention lays a foundation for the development of an efficient, low-cost, broad-spectrum subunit vaccine for porcine contagious pleuropneumonia, and provides an effective technical means for the prevention and treatment of the disease.

An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin / kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and / or with little or no measurable effect on liver function, as determined by ALT and AST measurements.

The present invention relates to an administration procedure to effectively treat a companion animal suffering from lung metastases. In particular, a nebulized BCG composition is delivered directly to the lungs to increase uptake therein and avoid loss of the active ingredient e.g. in the mucosa of the upper airways.

The present invention relates generally to fusion proteins containing a targeting sequence that targets the fusion protein to the outer spore wall of a member of the Bacillus cereus family. The invention also relates to recombinant Bacillus cereus family members expressing said fusion proteins and formulations containing said recombinant Bacillus cereus family members expressing said fusion proteins. Also described are methods of stimulating plant growth, protecting plants from pathogens, and improving stress resistance in plants by applying the recombinant Bacillus cereus family member or the formulation to a plant or plant growth medium. The invention also relates to a method for immobilizing spores of a recombinant Bacillus cereus family member expressing a fusion protein on a plant.

The invention discloses a streptococcus suis type 2 gene deletion strain as well as a construction method and application thereof, and belongs to the technical field of biological products. According to the invention, the B9H0105210 gene in the genome of the streptococcus suis serotype 2 SC19 is deleted in a homologous recombination manner for the first time, the hydrogen peroxide and nitric oxide stress resistance of the constructed streptococcus suis serotype 2 gene deleted strain is reduced, and the pathogenicity to mice is obviously weakened; moreover, the growth performance of the streptococcus suis type 2 gene-deleted strain is not greatly different from that of a wild strain SC19, the condition of gene recovery does not exist after continuous passage, and the streptococcus suis type 2 gene-deleted strain has an application prospect as an attenuated live vaccine, has a good immune protection effect on different genotypes of streptococcus suis such as the streptococcus suis type 2 strain SC19 and streptococcus suis type 2 P1 / 7, and has a good application prospect. And a certain cross immune protection performance is achieved.

The invention relates to the technical field of gene engineering, and particularly discloses streptococcus agalactiae WC1535 delta cps delta hylB as well as a construction method and application thereof. The streptococcus agalactiae WC1535 [delta] cps [delta] hylB is preserved in Guangdong Microbial Culture Collection Center on February 28, 2025, the preservation number is GDMCC NO.65955, and the address of the preservation unit is the 5th building, No. 59 building, No. 100 Courtyard, Xianlie Middle Road, Guangzhou. Compared with a traditional single-fragment deletion method, the toxicity of the deletion strain is not prone to being enhanced, and compared with a traditional injection immune vaccine, the gene deletion strain is used for preparing the tilapia oral live vaccine, the immune operation is simpler, and more labor cost is saved.

The invention provides a Brucella immunosuppressive gene BtpB deletion vaccine as well as a preparation method and application thereof, and belongs to the technical field of vaccine strains. The invention provides a suicide plasmid for knocking out a BtpB gene in a bovine brucella A19 vaccine strain and a gene deletion strain prepared on the basis of the suicide plasmid, and the BtpB gene deletion is performed on the brucella A19 strain so as to achieve the purpose of modifying the A19 vaccine. The A19 delta BtpB deletion strain constructed by the invention can reduce damage to host visceral organs, can induce a mouse to generate a high-titer Brucella specific antibody IgG, can better induce the mouse to generate Th1 type cytokines, and can provide better protective efficacy for the mouse than an A19 vaccine strain, so that the A19 delta BtpB deletion strain can be used as a vaccine for the mouse. The A19 delta BtpB deletion strain is expected to become a novel Brucella gene deletion vaccine candidate, and a theoretical basis and a data support are provided for developing a novel Brucella gene deletion vaccine.

An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin / kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and / or with little or no measurable effect on liver function, as determined by ALT and AST measurements.

The invention discloses a Bordetella pertussis strain subjected to genetic intervention as well as a preparation method and application of the Bordetella pertussis strain. Compared with the Bordetella pertussis strain BAA-589, the Bordetella pertussis strain disclosed by the invention has the advantage that the Bordetella pertussis strain has an element for reducing the expression of the BP1569 gene. The bordetella pertussis strain provided by the invention has the effect of obviously increasing the yield of OMV, and has a good application prospect in promoting the development of bordetella pertussis OMV vaccines.

A method for modulation of an immune response utilizing chiral nanoparticles. The chiral nanoparticles can be synthesized from nanoparticle seed precursors using circularly polarized light. The chirality of the NPs can be measured using chirality measures such as the Osipov-Pickup-Dunmeur index, the Hausdorff chirality measure and by using circular dichroism spectra, g-factor spectra, and maximum g-factor for a specific wavelength. In-vivo tests in mice showed a 2.27-fold enhancement of immune cell maturation and 1584-fold enhancement of IgG production by L-nanoparticles versus D-nanoparticles. Both the in-vivo and in-vitro immune responses monotonically depend on the chirality, measured as g-factors, of the nanoparticles, indicating that nanoscale chirality of the nanoparticles can be used to regulate immune cell maturation. Finally, L-nanoparticles demonstrated 1258-fold higher efficiency as adjuvants for the H9N2 influenza virus versus D-nanoparticles or Alum, opening a path to utilization of nanoscale chirality in immunology.

The invention relates to the field of preparation of animal husbandry vaccines, in particular to a porcine circovirus, mycoplasma hyopneumoniae and haemophilus parasuis triple vaccine which comprises 30-50 parts of first bacterial liquid containing inactivated haemophilus parasuis; an adjuvant; 40 to 60 parts of a culture solution of a mycoplasma hyopneumoniae culture; 30-40 parts of a second bacterial liquid containing inactivated porcine circovirus; 1 to 10 parts of tween-80; 2-6 parts of aluminum stearate; 1 to 3 parts of interleukin; and 2-4 parts of squalane. The vaccine is mainly applied to prevention of porcine circovirus, mycoplasma hyopneumoniae and haemophilus parasuis for boars and piglets in a pig farm, reduces the multi-system failure syndrome, mycoplasma hyopneumoniae, polyserositis, arthritis and meningitis of weaned piglets in the pig farm and the morbidity of multi-infection-source successive infection, and improves the survival efficiency of the piglets.